These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30543921)

  • 1. Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis.
    Gomes JP; Santos L; Shoenfeld Y
    Clin Immunol; 2019 Feb; 199():25-28. PubMed ID: 30543921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature.
    Sanges S; Rivière S; Mekinian A; Martin T; Le Quellec A; Chatelus E; Lescoat A; Jego P; Cazalets C; Quéméneur T; Le Gouellec N; Senet P; Francès C; Deroux A; Imbert B; Fain O; Boukari L; Sené T; Deligny C; Mathian A; Agard C; Pugnet G; Speca S; Dubucquoi S; Hatron PY; Hachulla É; Launay D
    Autoimmun Rev; 2017 Apr; 16(4):377-384. PubMed ID: 28232167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.
    Agostini E; De Luca G; Bruni C; Bartoli F; Tofani L; Campochiaro C; Pacini G; Moggi-Pignone A; Guiducci S; Bellando-Randone S; Shoenfeld Y; Dagna L; Matucci-Cerinic M
    Autoimmun Rev; 2021 Dec; 20(12):102981. PubMed ID: 34718166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
    Raja J; Nihtyanova SI; Murray CD; Denton CP; Ong VH
    Rheumatology (Oxford); 2016 Jan; 55(1):115-9. PubMed ID: 26320139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis.
    Speca S; Farhat MM; Jendoubi M; Guerrier T; Sanges S; Staumont-Sallé D; Hachulla E; Dubucquoi S; Sobanski V; Collet A; Launay D
    Sci Rep; 2023 Sep; 13(1):15102. PubMed ID: 37700078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulins in systemic sclerosis management. A large multicenter experience.
    Tandaipan J; Guillén-Del-Castillo A; Simeón-Aznar CP; Carreira PE; De la Puente C; Narváez J; Lluch J; Rubio-Rivas M; Alegre-Sancho JJ; Bonilla G; Moriano C; Casafont-Sole I; García-Vicuña R; Ortiz-Santamaría V; Riera E; Atienza-Mateo B; Blanco R; Galisteo C; Gonzalez-Martin JJ; Pego-Reigosa JM; Pros A; Heredia S; Castellví I
    Autoimmun Rev; 2023 Nov; 22(11):103441. PubMed ID: 37708984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience.
    Perković D; Petrić M; Božić I; Borić K; Marasović Krstulović D; Radić M; Martinović Kaliterna D
    Wien Klin Wochenschr; 2021 Oct; 133(19-20):1070-1075. PubMed ID: 32451820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin--a preliminary report.
    Levy Y; Sherer Y; Langevitz P; Lorber M; Rotman P; Fabrizzi F; Shoenfeld Y
    Clin Rheumatol; 2000; 19(3):207-11. PubMed ID: 10870656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravenous immunoglobulin (IVIG)].
    Hara M
    Nihon Rinsho; 2009 Mar; 67(3):599-605. PubMed ID: 19280939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration.
    Matsuda KM; Yoshizaki A; Kuzumi A; Toyama S; Awaji K; Miyake T; Sato S
    Rheumatology (Oxford); 2023 Sep; 62(9):3139-3145. PubMed ID: 36825818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
    Sapir T; Blank M; Shoenfeld Y
    Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.
    Cantarini L; Rigante D; Vitale A; Napodano S; Sakkas LI; Bogdanos DP; Shoenfeld Y
    Immunol Res; 2015 Mar; 61(3):326-37. PubMed ID: 25550086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients.
    Chaigne B; Rodeia S; Benmostefa N; Bérézné A; Authier J; Cohen P; Régent A; Terrier B; Costedoat-Chalumeau N; Guillevin L; Le Jeunne C; Mouthon L
    Autoimmun Rev; 2020 Jan; 19(1):102431. PubMed ID: 31734403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases.
    Katz U; Shoenfeld Y; Zandman-Goddard G
    Curr Pharm Des; 2011; 17(29):3166-75. PubMed ID: 21864262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
    Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
    Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration.
    Matsuda KM; Sugimoto E; Ako Y; Kitamura M; Miyahara M; Kotani H; Norimatsu Y; Hisamoto T; Kuzumi A; Fukasawa T; Sato S; Yoshizaki A
    J Dermatol; 2024 Jun; 51(6):741-751. PubMed ID: 38558171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis.
    Clark KE; Etomi O; Denton CP; Ong VH; Murray CD
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S168-70. PubMed ID: 26315822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study.
    Nacci F; Righi A; Conforti ML; Miniati I; Fiori G; Martinovic D; Melchiorre D; Sapir T; Blank M; Shoenfeld Y; Pignone AM; Cerinic MM
    Ann Rheum Dis; 2007 Jul; 66(7):977-9. PubMed ID: 17344244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG.
    Kumar S; Singh J; Kedika R; Mendoza F; Jimenez SA; Blomain ES; DiMarino AJ; Cohen S; Rattan S
    Am J Physiol Gastrointest Liver Physiol; 2016 Jun; 310(11):G1052-60. PubMed ID: 27173508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review.
    Koczanowski S; Morrisroe K; Fairley J; Nikpour M; Oon S; Brown Z
    Semin Arthritis Rheum; 2024 Jun; 68():152471. PubMed ID: 38954999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.